Serum matrix metalloproteinase-3 in rheumatoid arthritis patients: Correlation with disease activity and joint destruction

摘要

Aim of the work This study was designed to measure the serum level of matrix metalloproteinase-3 (MMP-3) in rheumatoid arthritis (RA) patients and its correlation with functional status, disease activity and joint damage. Patients and methods The study included 50 RA patients satisfying 2010 ACR/EULAR classification criteria recruited from Bani-Suef University Hospital and 20 controls. Functional disability was assessed according to Modified Health Assessment Questionnaire (MHAQ). Disease activity score in 28-joints (DAS28) and visual analogue scale (VAS) of pain were evaluated. Radiological joint damage was assessed by Van der Heijde-modified Sharp Score (vdHSS). Serum levels of MMP-3 were measured for all subjects. Results RA patients (44 females and 6 males) had a mean age of 46.36 ± 13.63 years and disease duration of 5.6 ± 4.75 years. Serum MMP-3 levels were higher in patients than in controls (46.78 ± 46.99 versus 1.98 ± 1.71 ng/ml respectively, p = 0.0001) and significantly correlated with erythrocyte sedimentation rate ( p = 0.001) and were significantly higher in patients with positive C-reactive protein, rheumatoid factor and anti-cyclic citrullinated peptide ( p = 0.0001, p = 0.009, p = 0.042, respectively). MMP-3 significantly correlated with DAS28 ( p = 0.0001) and vdHSS ( r = 0.78, p = 0.0001) and a significant difference was shown in those with erosions compared to those without ( p = 0.001). Serum MMP-3 levels significantly correlated negatively with cumulative steroid dose ( r = ?0.2, p = 0.03) and were significantly higher in patients who never received disease-modifying antirheumatic drugs ( p = 0.001). There were no significant relations of MMP-3 with age, MHAQ, VAS for pain. Conclusion These results indicate that serum MMP-3 is a measurable, useful specific marker of disease activity and joint damage in RA patients.